Ostia Sciences Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $393K

  • Investors
  • 2

Ostia Sciences General Information

Description

Operator of a biotechnology company intended to develop innovative oral probiotics and biotherapeutics for improving global health outcomes. The company offers microbiome-based applications that modulate the microbiome, addressing a range of infectious diseases and immune disorders, enabling customers to experience enhanced oral and respiratory health through the power of beneficial microbes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 124 Edward Street
  • Toronto, Ontario M5G 1G6
  • Canada
+1 (647)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 124 Edward Street
  • Toronto, Ontario M5G 1G6
  • Canada
+1 (647)

Ostia Sciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ostia Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 19-Jul-2025 $393K Completed Generating Revenue
3. Seed Round 01-Oct-2024 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
1. University Spin-Out 01-Jan-2020 Completed Generating Revenue
To view Ostia Sciences’s complete valuation and funding history, request access »

Ostia Sciences Patents

Ostia Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026178627-A1 Enhanced production of phosphorylated lantibiotics Pending 28-Feb-2025
WO-2025227220-A1 S. salivarius strain, lanthipeptides and methods of use Pending 03-May-2024
EP-4476325-A1 Lanthipeptides and methods of use Pending 10-Feb-2022
EP-4476325-A4 Lanthipeptides and methods of use Pending 10-Feb-2022
US-20250144168-A1 Lanthipeptides and methods of use Pending 10-Feb-2022 A61K38/164
To view Ostia Sciences’s complete patent history, request access »

Ostia Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ostia Sciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Natural Products Canada Venture Capital Minority
University of Toronto University
To view Ostia Sciences’s complete investors history, request access »

Ostia Sciences FAQs

  • When was Ostia Sciences founded?

    Ostia Sciences was founded in 2019.

  • Where is Ostia Sciences headquartered?

    Ostia Sciences is headquartered in Toronto, Canada.

  • What is the size of Ostia Sciences?

    Ostia Sciences has 8 total employees.

  • What industry is Ostia Sciences in?

    Ostia Sciences’s primary industry is Drug Discovery.

  • Is Ostia Sciences a private or public company?

    Ostia Sciences is a Private company.

  • What is Ostia Sciences’s current revenue?

    The current revenue for Ostia Sciences is .

  • How much funding has Ostia Sciences raised over time?

    Ostia Sciences has raised $1.08M.

  • Who are Ostia Sciences’s investors?

    Natural Products Canada and University of Toronto have invested in Ostia Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process